HistoIndex has partnered with Houston Research Institute and Knowledge Research Center to expand access to AI-driven digital pathology for liver disease diagnostics in Texas and California.
A new analysis finds that policy and payment gaps are limiting access to diagnostics, with nearly half the world lacking adequate testing and reimbursement lagging behind advances in precision therapies.
Boston Cell Standards’ immunohistochemistry reference materials have entered the FDA’s Medical Device Development Tools qualification phase, advancing efforts to standardize IHC assay performance in cancer diagnostics.
NeoGenomics has integrated its oncology testing portfolio with Epic Aura, allowing physicians nationwide to order tests and view results within the Epic EHR system, aiming to streamline workflows and expand test adoption, according to the company.
Circulating tumor DNA testing may help predict metastatic risk in muscle-invasive bladder cancer patients opting for bladder-sparing treatment, according to Fox Chase Cancer Center researchers, though additional biomarkers are needed for local recurrence.
